In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes

被引：0
|
作者：
Yoon, Jongmin
Song, Haengjin
Lee, Don-Gil
Kim, Jung Ho
Hong, Dahae
Shin, Chorong
Jang, Eunhye
Kim, Jisu
Lee, Seolhee
Jun, Yearin
An, Kyungmi
Hong, Chang-Hee
Kwak, Hyun-Jung
Je, In-Gyu
Song, Hyo-Jung
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-122-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
122-LB
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    Kim, Jung Ho
    Lee, Seolhee
    Shin, Chorong
    Jun, Yearin
    Hong, Dahae
    Lee, Don-Gil
    Jang, Eunhye
    Kim, Jisu
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2021, 70
  • [2] In Vitro DILI Risk Assessment of IDG16177, a Potent and Selective GPR40 Agonist, for the Treatment of Type 2 Diabetes
    Yoon, Jongmin
    Song, Haengjin
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Song, Hyo-Jung
    DIABETES, 2022, 71
  • [3] IDG-16177, a Potent, Orally-Bioavailable GPR40 Agonist, Improves Glycemic Control and Glucose-Stimulated Insulin Secretion in Preclinical Studies
    Yoon, Jongmin
    Lee, Don-Gil
    Kim, Jung Ho
    Hong, Dahae
    Shin, Chorong
    Jang, Eunhye
    Kim, Jisu
    Song, Haengjin
    Lee, Seolhee
    Jun, Yearin
    An, Kyungmi
    Hong, Chang-Hee
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2021, 70
  • [4] Preclinical Development of IDG-164177 as a Potent GPR40 Agonist for Treatment of Type 2 Diabetes
    Yoon, Jong Min
    Kim, Dohee
    Lee, Don-Gil
    An, Kyung Mi
    Lee, Myong Jae
    Hong, Chang-Hee
    Hong, Dahae
    Kwak, Hyun-Jung
    Je, In-Gyu
    Song, Hyo-Jung
    DIABETES, 2020, 69
  • [5] ZYDG2, a Potent, Selective, and Safe GPR40 Agonist for Treatment of Type 2 Diabetes
    Jain, Mukul R.
    Giri, Suresh R.
    Trivedi, Chitrang J.
    Bhoi, Bibhuti B.
    Rath, Akshyaya Chandan
    Rathod, Rohan Manubhai
    Sundar, Rajesh
    Bandyopadhyay, Debdutta
    Ramdhave, Rashmi
    Patel, Gautam D.
    Srivastava, Brijesh Kumar
    Desai, Ranjit C.
    DIABETES, 2018, 67
  • [6] CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes
    Bazydlo-Guzenda, Katarzyna
    Buda, Pawel
    Kozlowska, Izabela
    Mach, Mateusz
    Teska-Kaminska, Malgorzata
    Stelmach, Filip
    Wasinska-Kalwa, Malgorzata
    Galazka, Kinga
    Dubiel, Krzysztof K.
    Pieczykolan, Jerzy S.
    Wieczorek, Maciej
    DIABETES, 2019, 68
  • [7] Discovery of ZYDG2: a potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes
    Jain, Mukul R.
    Giri, Suresh R.
    Trivedi, Chitrang J.
    Bhoi, Bibhuti B.
    Rath, Akshyaya Chandan
    Rathod, Rohan M.
    Sundar, Rajesh
    Bandyopadhyay, Debdutta
    Ramdhave, Rashmi
    Patel, Gautam D.
    Srivastava, Brijesh Kumar
    Desai, Ranjit C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (04):
  • [8] Discovery of ID11014A as a Novel GPR40 Agonist for the Treatment of Type 2 Diabetes
    An, Kyungmi
    Hong, Changhee
    Cui, Shuolin
    Kwak, Hyunjung
    Song, Hyojung
    Park, Joontae
    Moon, Anna
    Kim, Jeongah
    Yang, Jihun
    Lee, Jungwoo
    Yoon, Jongmin
    Lee, Myongjae
    Jeong, Donggu
    Kim, Dohee
    Lee, Dongil
    Koh, Eunji
    Shin, Jeongcheol
    Hong, Dahae
    Park, Jun-Gu
    Je, In-Gyu
    Lee, Seolhee
    Lee, Hongsub
    Park, Soobong
    Kang, Jaehoon
    DIABETES, 2017, 66 : LB40 - LB40
  • [9] GPR40 full agonists for the treatment of type 2 diabetes
    Player, Mark
    Meegalla, Sanath
    Huang, Hui
    Martin, Tonya
    Xu, June Zhi
    Zhao, Shuyuan
    Liu, Jianying
    Towers, Meghan
    Gunnet, Joseph
    Wang, Yuanping
    Lee, Seunghun
    Silva, Jose
    Otieno, Monicah
    Arnoult, Eric
    Pocai, Alessandro
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [10] Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
    Burant, Charles F.
    DIABETES CARE, 2013, 36 : S175 - S179
12345